Navigation Links
Palomar and Q-MED AB Enter Into International Distribution Agreement
Date:1/9/2008

hetic medical professional market with R&D and evidence based products, that very well match Restylane range of products and other present and future products Q-MED brings to medical professionals around the world. We are excited to be participating in what is the first time that two companies from very different aesthetic industry segments have entered into such a collaboration."

For more information, please see the International Distributor Agreement filed as Exhibit 10.1 to a Current Report on Form 8-K filed today.

About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the- counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has an agreement with The Gillette Company to develop and commercialize home-use, light-based devices for women for hair removal and an agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light- based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or prev
'/>"/>

SOURCE Palomar Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
2. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
3. Murray Leads Delegation in Securing $2.1 Million for Proton Therapy Center
4. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
5. AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou, China
6. Nano-Science Center to coordinate EU-project
7. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
8. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. Embla Systems in Collaboration with Beth Israel Deaconess Medical Center to Develop Cardio-Pulmonary Coupling Technology
11. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... vein treatment methods led by Dr. Sinjae Hyun, associate professor of biomedical ... he will present this summer to his research collaborators and the company. ... ... California company aided in the research of vein treatment methods ...
... Therapeutics, Inc. (CTI),(Nasdaq and MTA: CTIC) announced today ... accepted for filing and review, and has granted,priority ... for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation,therapy ... achieve,a response to first-line therapy. Priority review is ...
... ENCO ), a full service multinational clinical ... many of the world,s leading,pharmaceutical and biotechnology companies, today ... from Nasdaq stating that since it had not yet,filed ... 2008 as of the,date of the letter, it was ...
Cached Biology Technology:Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 2FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 3FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 5Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 2Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing 3
(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst firm ... half of the world,s population will have a chip-based ... Europe . Asia , ... market accounting for more than 60% of all National ... Acuity,s report  -- "The Global National eID ...
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2
... DURHAM, N.C. Under the microscope, the bacteria start dividing ... on. But then individual cells begin "popping," like circus balloons ... Duke University bioengineers who captured it on video, turns out ... must be considered by scientists creating living, synthetic circuits out ...
... professor Kam Tang of the Virginia Institute of Marine ... fleas" play an important role in carrying hitchhiking bacteria ... article, "Bacteria dispersal by hitchhiking on zooplankton," appeared in ... the National Academy of Sciences . It was co-authored ...
... - Greenhouse gas markets, where invisible gases are ... people. Farmers can make money on these markets, ... methane capture technologies in animal-based systems, no-till farming, ... extension educators, offset aggregators, and other stakeholders need ...
Cached Biology News:Popping cells surprise living circuits creators 2Popping cells surprise living circuits creators 3Study shows that hitchhiking bacteria can go against the flow 2Study shows that hitchhiking bacteria can go against the flow 3Greenhouse gas calculator connects farming practices with carbon credits 2
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
MOUSE ANTI DUCK IgY LIGHT CHAIN...
Kit for Detection of Mitochondrial Membrane Potential...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
Biology Products: